PFE
Pfizer Inc.
—
25.22 $
-0.7000 (%-2.70)
Previous Close: 25.92
Day Low₺24.94
Day High₺25.66
PFE: Pfizer Inc. Financials
PFE Income Statement
Total revenue
Net income
Gross margin TTM
70.33%
Operating margin TTM
24.67%
Net profit margin TTM
12.42%
Return on investment TTM
—
| Period end | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 62,579,000,000 | 63,627,000,000 | 59,553,000,000 | 100,330,000,000 |
| Operating income | 15,437,000,000 | 16,483,000,000 | 5,292,000,000 | 37,549,000,000 |
| Net income | 7,770,000,000 | 8,020,000,000 | 2,133,000,000 | 31,365,000,000 |
All line items
| Line item | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 62,579,000,000 | 63,627,000,000 | 59,553,000,000 | 100,330,000,000 |
| Cost of revenue | 18,565,000,000 | 21,781,000,000 | 29,213,000,000 | 38,240,000,000 |
| Gross profit | 44,014,000,000 | 41,846,000,000 | 30,340,000,000 | 62,090,000,000 |
| Research and development expenses | 11,976,000,000 | 10,738,000,000 | 10,578,000,000 | 11,426,000,000 |
| General and administrative expenses | 0 | 11,471,000,000 | 0 | 0 |
| Selling and marketing expenses | 0 | 3,300,000,000 | 0 | 0 |
| Selling, general and administrative expenses | 13,346,000,000 | 14,730,000,000 | 14,470,000,000 | 13,115,000,000 |
| Other expenses | 3,255,000,000 | -105,000,000 | 0 | 0 |
| Operating expenses | 28,577,000,000 | 25,363,000,000 | 25,048,000,000 | 24,541,000,000 |
| Cost and expenses | 47,142,000,000 | 47,144,000,000 | 54,261,000,000 | 62,781,000,000 |
| Net interest income | -2,068,000,000 | -2,546,000,000 | -585,000,000 | -987,000,000 |
| Interest income | 603,000,000 | 545,000,000 | 1,624,000,000 | 251,000,000 |
| Interest expense | 2,671,000,000 | 3,091,000,000 | 2,209,000,000 | 1,238,000,000 |
| Depreciation and amortization | 4,905,000,000 | 7,013,000,000 | 6,290,000,000 | 5,064,000,000 |
| EBITDA | 15,096,000,000 | 18,127,000,000 | 9,557,000,000 | 41,031,000,000 |
| EBIT | 10,191,000,000 | 11,114,000,000 | 3,267,000,000 | 35,967,000,000 |
| Non-operating income (excl. interest) | 5,246,000,000 | 5,369,000,000 | 2,025,000,000 | 1,582,000,000 |
| Operating income | 15,437,000,000 | 16,483,000,000 | 5,292,000,000 | 37,549,000,000 |
| Total other income/expenses (net) | -7,917,000,000 | -8,460,000,000 | -4,234,000,000 | -2,820,000,000 |
| Income before tax | 7,520,000,000 | 8,023,000,000 | 1,058,000,000 | 34,729,000,000 |
| Income tax expense | -266,000,000 | -28,000,000 | -1,114,000,000 | 3,328,000,000 |
| Net income from continuing operations | 7,786,000,000 | 8,051,000,000 | 2,172,000,000 | 31,401,000,000 |
| Net income from discontinued operations | 25,000,000 | 11,000,000 | 0 | -1,000,000 |
| Other adjustments to net income | 0 | 0 | 0 | 0 |
| Net income | 7,770,000,000 | 8,020,000,000 | 2,133,000,000 | 31,365,000,000 |
| Net income deductions | 0 | -11,000,000 | 14,000,000 | 0 |
| Bottom line net income | 7,745,000,000 | 8,031,000,000 | 2,119,000,000 | 31,365,000,000 |
| EPS | 1 | 1 | 0.3755 | 6 |
| Diluted EPS | 1 | 1 | 0.3712 | 5 |
| Weighted average shares outstanding | 5,682,759,000 | 5,664,000,000 | 5,643,000,000 | 5,608,000,000 |
| Weighted average diluted shares outstanding | 5,686,000,000 | 5,700,000,000 | 5,709,000,000 | 5,733,000,000 |